Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Still a Buy?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) shares gapped up before the market opened on Tuesday . The stock had previously closed at $18.90, but opened at $19.74. Daiichi Sankyo shares last traded at $19.74, with a volume of 457 shares trading hands.

Wall Street Analyst Weigh In

Several research analysts recently commented on DSNKY shares. Zacks Research cut Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. Jefferies Financial Group downgraded shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Daiichi Sankyo has a consensus rating of “Reduce”.

Daiichi Sankyo Stock Down 2.3%

The stock has a market capitalization of $34.57 billion, a P/E ratio of 21.58, a P/E/G ratio of 2.59 and a beta of -0.11. The company has a current ratio of 2.92, a quick ratio of 1.96 and a debt-to-equity ratio of 0.29. The firm’s fifty day moving average is $17.63 and its 200-day moving average is $17.26.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings data on Friday, July 31st. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a return on equity of 14.35% and a net margin of 10.92%.The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, equities research analysts predict that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 earnings per share for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.